Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Hypoxia 4Melanoma 3Prostatic Neoplasms 2Pancreatic Neoplasms 2Tongue Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Sarcoma 1Rectal Neoplasms 1Neoplasms 1Immune System Diseases 1Head and Neck Neoplasms 1

Interventions

Cyclophosphamide 14fludarabine 9fludarabine phosphate 8Busulfan 5Bendamustine Hydrochloride 5Tacrolimus 4Rituximab 4Mycophenolic Acid 4ibrutinib 3Melphalan 3Bortezomib 3AP 1903 reagent 3tetulomab tetraxetan lu-177 2ponatinib 2pembrolizumab 2cobomarsen 2Whole-Body Irradiation 2Vorinostat 2Vincristine 2Prednisone 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mesna 2Lutetium 2Etoposide 2Doxorubicin 2Brentuximab Vedotin 2Bone Marrow Transplantation 2thymoglobulin 1pimonidazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Immune System Diseases × pimonidazole × Clear all
NCT04658303 2025-05-08

Evolution of Metabolic and Immune Dysfunction in In-transit Melanoma

University of Pittsburgh

Recruiting
20 enrolled
Dermatologic

Immune System Diseases, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡